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Abstract
Introduction In general, women more often experience metformin-associated adverse drug reactions (ADRs) than men.
Objectives We aimed to assess whether sex differences in reported ADRs for metformin are observed at different times after 
initiation, and to explore their concurrence with sex differences in the dose of metformin over time. This may guide future 
studies in assessing the involved mechanisms of sex differences in metformin-associated ADRs and may guide sex-specific 
management of ADRs in clinical practice.
Methods This study has a longitudinal design using data about patients initiating metformin collected by the Dutch National 
Pharmacovigilance Center Lareb through their Intensive Monitoring program. Patients were asked to complete a web-based 
questionnaire six times after initiation (i.e., at 2 weeks, 6 weeks and at 3, 6, 9, and 12 months). The outcome variables were 
the proportion of patients reporting any ADR (primary) and the dose of metformin (secondary). Sex differences in the pro-
portions of ADRs and in the dose were tested at each assessment using Pearson Chi-Squared tests and Wilcoxon rank-sum 
tests, respectively. Using Bonferroni adjustment for multiple testing, a p value < 0.01 was considered statistically significant.
Results The number of included patients was 1712 (40.9% women). Women reported an ADR more often than men, which 
was statistically significant at the assessment at 2 weeks (34% vs 25%, p < 0.001), and 6 weeks (37% vs 28%, p = 0.001) after 
initiation. In general, women were reported to be prescribed a lower dose than men, which became statistically significant 
at the 9-month assessment (p < 0.01).
Conclusions Sex differences in reported ADRs were seen in the first weeks after metformin initiation, whereas statistically 
significant differences in self-reported prescribed dosing were observed after several months. Patients, in particular women, 
might benefit from being prescribed lower metformin doses at treatment initiation.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-020-00913 -8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Metformin is the most commonly prescribed and guideline-
recommended initial glucose-lowering drug for people with 
type 2 diabetes mellitus due to its well-known safety profile, 
demonstrated cardiovascular benefits, and low costs [1–4]. 
Nevertheless, metformin-associated adverse drug reactions 
(ADRs) are common, particularly gastrointestinal com-
plaints such as diarrhea, nausea, and abdominal discomfort. 
A previous study showed that 35% of patients initiating met-
formin reported at least one ADR during a 1-year follow-up 
period [5]. This proportion was higher among women than 
among men (40% vs 31%) [5].
In general, metformin-associated ADRs are transient and 
dose-related and can be minimized by initiating at a low 
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dose, taking the drug with or after a meal, slowly increasing 
the dose, or if necessary, switching to the extended-release 
preparation [6–9]. Given the higher proportion of women 
experiencing ADRs of metformin than men, it seems that 
ADRs may be less transient in women or that minimization 
strategies are not sufficiently applied for women. An analysis 
of prescription data from general practitioners suggests that 
women are generally prescribed a lower metformin dose at 
initiation and during a 1-year follow-up period than men 
[see Electronic Supplementary Material (ESM) 1], but its 
association with experienced ADRs over time has not been 
assessed.
The aim of our study was to extend our knowledge on sex 
differences in metformin-associated ADRs and the associa-
tion with drug dosing. More specifically, we aimed to assess 
whether sex differences in reported ADRs for metformin are 
observed at different times after initiation, and to explore 
their concurrence with sex differences in the self-reported 
prescribed dose of metformin over time. Information about 
the course of sex differences in ADRs and drug dosing over 
time may guide future studies in assessing the involved 
mechanisms of sex differences in metformin-associated 
ADRs and may guide sex-specific management of ADRs in 
clinical practice.
2  Methods
2.1  Study Design and Data Source
This study has a longitudinal design in which data from the 
Lareb Intensive Monitoring (LIM) program of the Dutch 
National Pharmacovigilance Center Lareb were used. In 
LIM, patients were included when they signed up for the 
study after having received a leaflet from the pharmacist 
during the first dispensing of a drug of interest. Several 
antidiabetic drugs have been assessed using LIM, including 
metformin. Patients in LIM were followed for a maximum 
period of 12 months, in which they were asked to complete 
(six times) a web-based questionnaire about experienced 
ADRs and additional questions including the dose of the pre-
scribed drug. The questionnaire was sent 2 weeks, 6 weeks, 
3 months, 6 months, 9 months, and 12 months after treat-
ment initiation. Patients were asked to report possible ADRs 
experienced in the period since the previous assessment (i.e., 
0–2 weeks, 2–6 weeks, 6 weeks to 3 months, 3–6 months, 
6–9 months, and 9–12 months). The answers given by the 
patients on a previous questionnaire were presented in the 
next questionnaire so that the patients only needed to adapt 
the aspects that changed during follow-up. Possible ADRs 
were events considered to be related to the use of the drug 
under study by the patient. The LIM procedures have been 
described in more detail previously [10–12].
2.2  Population
Patients participating in LIM and initiating metformin 
between February 2008 and May 2012 were included in this 
study. Some patients did not complete the questionnaire at 
all six assessments. Data for these patients were included 
for the available follow-up period from inclusion until the 
assessment with missing data. This implies that question-
naires completed by these patients after the missing assess-
ment were excluded. Furthermore, patients were excluded 
when they completed a follow-up questionnaire for an anti-
diabetic drug other than metformin.
2.3  Outcomes and Determinant
The primary outcome was the proportion of patients report-
ing any ADR. ADRs reported in the questionnaires by the 
patients were classified by trained assessors at the pharma-
covigilance center according to the Medical Dictionary for 
Regulatory Activities (MedDRA), version 20.0 [13].
The secondary outcome was the dose of metformin. The 
daily dose of metformin was based on the information on 
the dose and the frequency per day reported by the patients 
in the questionnaire. A reported value for the dose that is 
implausible (i.e., lower than the start dose of 500 mg or 
higher than the maximum recommended dose of 3000 mg 
in the Netherlands) [14] and values other than numbers for 
the frequency (i.e., “continuously”, “according to scheme”, 
and “if necessary”) were coded as missing.
The determinant used in this study was the sex (i.e., 
women vs men) of the patients.
Key Points 
A higher proportion of women reporting metformin-
associated adverse drug reactions (ADRs) is seen, 
particularly at early stages after initiation.
The reduction of sex differences in ADR reporting 
over time is accompanied by a lower self-reported dose 
increase of metformin among women at later stages after 
initiation.
Patients, in particular women, might benefit from being 
prescribed lower metformin doses at treatment initiation.
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2.4  Analyses
Descriptive statistics were used to present the proportion 
of patients reporting an ADR, the most commonly reported 
ADRs, and the self-reported prescribed dose of metformin 
over time. Sex differences in the proportions of reported 
ADRs and in the dose of metformin were tested at each 
assessment using Pearson Chi-Squared tests and Wilcoxon 
rank-sum tests, respectively. Sensitivity analyses were con-
ducted in which only patients who completed the question-
naire at all six assessments were included. The analyses 
were conducted using  Stata® version 14 (Stata Corp., Col-
lege Station, TX, USA). Using Bonferroni adjustment for 
multiple testing, a p value < 0.01 was considered statistically 
significant. Figures were made using Microsoft  Excel® 2010 
(Microsoft Corp., Redmond, WA, USA).
3  Results
In total, 1712 patients participated in this study (average age 
58 years (SD 12), 40.9% women) (Table 1). Men were, on 
average, 60 years of age at the time of metformin initiation, 
whereas women were, on average, 55 years of age (Table 1). 
The questionnaire was completed at all six assessments by 
474 patients (average age 59 years (SD 11), 36.9% women). 
Of all patients, 41% reported at least one ADR during fol-
low-up (37% of the males and 46% of the females), with 
a total of 2673 ADRs at the Preferred Term level of the 
MedDRA (1395 by males and 1278 by females). The most 
commonly reported ADRs were diarrhea, nausea, abdominal 
discomfort, flatulence, headache, and fatigue (Table 1).
3.1  Sex Differences in the Proportion of Reported 
ADRs Over Time
In the first period of 2 weeks after metformin initiation, 25% 
of the men reported to have experienced an ADR compared 
with 34% of the women. These numbers were somewhat 
higher in the periods between 2 and 6 weeks and between 
6 weeks and 3 months after initiation and decreased in the 
following assessments. The proportion of women and men 
was relatively similar over time for the most commonly 
reported ADRs. Women generally reported an ADR more 
often than men, which was statistically significant for the 
first two assessments (at 2 weeks: 34% vs 25%, p < 0.001; at 
6 weeks: 37% vs 28%, p = 0.001 for women vs men, respec-
tively; Fig. 1). A similar pattern was seen in the sensitiv-
ity analysis in which only patients who completed all six 
assessments were included, although it was only considered 
statistically significant at 6 weeks (Fig. S1 in ESM 2).
3.2  Sex Differences in Metformin Dose Over Time
The average dose of metformin increased in the study popu-
lation from 821 mg at 2 weeks to 1115 mg at 12 months 
(Table S1 in ESM 2). Average doses increased slightly more 
for men (from 830 to 1161 mg) than for women (from 809 
to 1034 mg) (Fig. 2; Table S1 in ESM 2). Doses appeared to 
be higher for men at each assessment, but this was consid-
ered statistically significant only at the 9-month assessment 
(p < 0.01; Fig. 2). In the sensitivity analyses that included 
only patients who completed all six assessments, the doses 
for women were significantly lower than the doses for men 
at the 2-week assessment (Fig. S2 and Table S2 in ESM 
2). The average initial dose for women completing all six 
assessments was 717 mg, whereas this was 836 mg for men.
4  Discussion
A higher number of women reporting an ADR was primar-
ily seen in the first weeks after metformin initiation. The 
reduction of sex differences in ADR reporting over time was 
accompanied by a lower dose of metformin among women 
at later stages after initiation.
Previous studies indicate that women more often report 
an ADR than men for drugs in general [15–18], as well as 
for metformin specifically [5, 19]. The current study adds to 
this knowledge that sex differences in metformin-associated 
ADRs are particularly shown at early stages after initia-
tion. There could be several explanations for this finding. 
First, the experience of ADRs may lead to discontinuation 
of metformin treatment and therefore a loss to follow-up 
of the patients experiencing ADRs in the current study. 
The reasons for drop-out in our study are unknown but the 
Table 1  Descriptive statistics of the included patients
Total Men Women
Number of patients (%) 1712 1011 (59.1) 701 (40.9)
Average age in years (SD) 58 (12) 60 (10) 55 (12)
Number of patients (%) per time period
2 weeks 1712 1011 (59.1) 701 (40.9)
6 weeks 1336 808 (60.5) 528 (39.5)
3 months 1050 637 (60.7) 413 (39.3)
6 months 813 504 (62.0) 309 (38.0)
9 months 615 386 (62.8) 229 (37.2)
12 months 474 299 (63.1) 175 (36.9)
Most commonly reported ADRs, N (%)
Diarrhea 662 351 (53.0) 311 (47.0)
Nausea 247 82 (33.2) 165 (66.8)
Abdominal discomfort 183 98 (53.6) 85 (46.4)
Flatulence 164 95 (57.9) 69 (42.1)
Headache 137 68 (49.6) 69 (50.4)
Fatigue 113 64 (56.6) 49 (43.4)
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Fig. 1  Proportion with 95% 
confidence interval (CI) of 
women and men reporting an 
adverse drug reaction (ADR) 
for metformin and an overview 
of the most commonly reported 
ADRs at each assessment. *Sta-
tistically significant differences 
































Women 33,52% 36,55% 34,14% 26,54% 21,83% 17,14%
Men 24,83% 28,09% 27,00% 23,81% 17,88% 16,72%
P-value <0.001* 0.001* 0.013 0.382 0.230 0.906
Most commonly reported ADRs, N (%)
Diarrhea 202 172 127 82 47 32
Women 96 (48) 86 (50) 60 (47) 39 (48) 19 (40) 11 (34)
Men 106 (52) 86 (50) 67 (53) 43 (52) 28 (60) 21 (66)
Nausea 97 71 41 23 8 7
Women 68 (70) 49 (69) 26 (63) 14 (61) 5 (62) 3 (43)
Men 29 (30) 22 (31) 15 (37) 9 (39) 3 (38) 4 (57)
Abdominal discomfort 57 50 37 23 9 7
Women 28 (49) 23 (46) 17 (46) 11 (48) 4 (44) 2 (29)
Men 29 (51) 27 (54) 20 (54) 12 (52) 5 (56) 5 (71)
Flatulence 32 35 34 26 20 17
Women 12 (38) 14 (40) 14 (41) 9 (35) 10 (50) 10 (59)
Men 20 (62) 21 (60) 20 (59) 17 (65) 10 (50) 7 (41)
Headache 52 41 28 9 4 3
Women 27 (52) 19 (46) 13 (46) 4 (44) 4 (100) 2 (67)
Men 25 (48) 22 (54) 15 (54) 5 (56) 0 (0) 1 (33)
Fatigue 28 32 27 12 9 5 
Women 12 (43) 16 (50) 13 (48) 4 (33) 3 (33) 1 (20)
Men 16 (57) 16 (50) 14 (52) 8 (67) 6 (67) 4 (80)
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proportion of men who completed all six assessments in this 
study was somewhat higher than the proportion of women. 
However, the number of both men and women reporting 
an ADR was somewhat higher for those who completed all 
six assessments (25.1% and 36.0%, respectively, at the first 
assessment) than those in the total study population (24.8% 
vs 33.5%, respectively, at the first assessment), refuting that 
patients experiencing an ADR in the first weeks after treat-
ment initiation dropped out of the study. Also, the same pat-
tern of sex differences in ADRs over time was shown in the 
sensitivity analyses, in which only patients who completed 
the six assessments were included.
Another explanation could lie in sex differences in the 
dose of metformin. The most commonly reported ADRs 
among both men and women were diarrhea, nausea, abdomi-
nal discomfort, flatulence, headache, and fatigue. Most of 
these are Type A effects, suggesting that they could be 
avoided by using the appropriate dose for an individual [20]. 
The average dose of metformin at initiation was somewhat 
lower for women than for men. Over time, this difference 
became larger, suggesting that women received fewer up 
titrations and/or more dose reductions, and was accompanied 
by fewer ADRs reported by women in these later months. In 
the sensitivity analysis, women who completed all assess-
ments initiated on lower doses than men who completed 
all assessments, but also on lower doses than women who 
did not complete all assessments. This suggests that women 
starting on low doses are more likely to tolerate metformin 
treatment up to 1 year of follow up. A post-hoc analysis 
showed that both men and women who reported an ADR 
were generally on a higher dose than those who did not 
report an ADR (Fig. S3 in ESM 2). This indicates that the 
advice to start with a low dose and up titrate slowly [6, 7, 
9] is relevant for both women and men, and that healthcare 
professionals should pay attention to this advice to reduce 
the burden of ADRs among their patients. Further studies 
are needed to assess the underlying factors of the potential 
sex difference of metformin dose on experiencing ADRs. A 
factor that may be important to take into account is some-
one’s weight. Previously it was shown that sex differences 
in pharmacokinetics can be due to weight differences [21].
Finally, it could also be that ADRs among women are 
more often of a transient nature or that women adapt to or 
handle ADRs differently than men. A previous study showed 
that ADRs experienced by people with diabetes can be tran-
sient or fluctuating over time [22] but it is not clear whether 
Fig. 2  Average dose in 
milligrams and 95% confi-
dence interval (CI) of self-
reported dose of metformin 
at each assessment and per 
sex.*Statistically significant 







































Women 809 897 985 1004 984 1034
Men 830 932 1029 1066 1113 1161
P-value 0.225 0.113 0.131 0.156 <0.01* 0.037
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this differs between men and women. This could in part be 
a gender-related factor, since social, behavioral, and cul-
tural differences between men and women may influence 
the experience and reporting of ADRs [15, 23, 24]. Women 
and men have different risk perceptions [25] and it has been 
shown that women more often read patient information 
leaflets than men [26]. Such differences should be included 
when investigating explanations for the observed sex differ-
ences in ADRs associated with metformin that were shown 
particularly at early stages after initiation.
The main strength of this study is the longitudinal data 
collection where patients were followed for a period of 
12 months. Therefore, sex differences could be assessed at 
different times after treatment initiation. A limitation of the 
study is the low number of patients that completed all six 
assessments (i.e., 28% of the patients). These numbers are 
somewhat lower than intensive monitoring studies of dulox-
etine (39%) and pregabalin (38%) [10, 27]. The follow-up 
period in these studies was, however, shorter (i.e., 6 months), 
so a further decrease in the number of participants in our 
study may have been due to the longer follow-up. In general, 
patients experiencing an ADR may be more motivated to 
complete a questionnaire about ADRs [5]. This might have 
led to more women completing all questionnaires, but that 
was not the case in our study. Another limitation of this study 
is the unavailable information about other patient character-
istics (e.g., body weight, diabetes duration, and glomerular 
filtration rate), for which we could not adjust. Further studies 
should assess the role of such characteristics on the observed 
differences between men and women in ADRs. We did not 
conduct a formal causality assessment since the focus is on 
patient-reported ADRs for metformin. A general limitation 
of studies using questionnaires is the representativeness of 
the responders. A previous study showed some differences 
between the patient population in the LIM diabetes study 
and an external reference population [12]. More specifically, 
the LIM population was somewhat younger, healthier, and 
included more men than the reference population, which 
may have led to an underestimation of ADRs.
5  Conclusion
Sex differences in reported ADRs were mainly observed 
during the first weeks after metformin initiation, whereas 
differences in self-reported prescribed dosing became sig-
nificant after several months. Patients, in particular women, 
might benefit from being prescribed a lower dose of met-
formin at initiation to reduce the risk of ADR occurrence.
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